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Summary
It is generally thought that future advances in the treatment and cure of breast cancer patients will be made possible
through a deeper understanding of tumor biology and an improved capability to define the prognosis of each single
patient. This will lead to the formulation of new, more selective, and patient-tailored therapies. It is therefore
important, when studying potential prognostic factors, to follow methodologic requirements and guidelines which
involve the carrying out of prospective studies as confirmatory steps. Repeatedly or recently investigated prognostic
markers (tumor size, menopausal status, ER, PgR, 3H thymidine labeling index, c-erbB-2 and p27 expression)
were evaluated on a series of 286 prospectively recruited node negative breast cancer patients who underwent
loco-regional treatment alone and were closely followed. The individual and relative prognostic contribution of
each variable with respect to other factors, as well as their ability to identify node negative patients at risk, were
assessed by univariate and multivariate analysis. At a five-year follow-up, only tumor size (pD 0.021) and TLI
(pD 0.016) individually proved to be significant prognostic indicators of relapse-free survival. Conversely, p27
expression was not related to RFS and c-erbB-2 expression appeared to have only a short-term effect on patient
prognosis. TLI and tumor size, tested in multivariate analysis along with ER and menopausal status, maintained
their independent prognostic relevance. The study, performed on a large series of node-negative patients given
loco-regional treatment alone, for the first time prospectively recruited, showed the prognostic relevance of TLI
and its independence from other clinico-pathologic and biologic factors over a five-year period.
Introduction
Public awareness and widespread information cam-
paigns about cancer prevention programs and mam-
mographic screenings have led, in the last decade,
to an earlier detection of breast cancer. The propor-
tion of women with newly-diagnosed small and node-
negative disease is therefore increasing and represents
a new reality to be approached.
Consolidated clinical experience has demonstrated
that about a quarter of node-negative breast cancer pa-
tients are destined to relapse and die from the disease
after loco-regional treatment alone. Recent studies
have also shown that adjuvant therapy improves the
clinical outcome of node-negative patients [1–4], but
the benefits and risks of therapy must be weighted
in terms of both toxicity and cost. The clinical and
biologic heterogeneity of breast cancer has led most
clinicians to believe that the risk-to-benefit ratio does
not favour treatment of all node-negative tumors. Con-
sequently, an accurate prediction of the course of
disease in individual patients is needed in order to
identify those at risk who are candidates for adjuvant
systemic treatment. It is also important for evaluat-
ing whether the patient could benefit from a particular
type of therapy or should be spared the toxicity of
ineffective treatment.
Over the past 20 years, new technologies have led
to the proposal of an ever increasing number of po-
tential prognostic factors for breast cancer patients.
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As a result, clinicians are often faced with difficulties
when trying to integrate the new and conventional pro-
gnostic factors in treatment decision-making. Further-
more, most studies have examined new biologic vari-
ables individually and almost always by retrospective
analysis.
Current information in literature highlights the
complexity of biologic processes underlying tumor
transformation and progression such as gene altera-
tions, cell differentiation and proliferation, apoptosis
and invasiveness [5–18]. Moreover, much is now
known of the multiplicity of cellular, biochemical and
genetic markers representative of different biologic as-
pects. The large body of information derived from
retrospective studies enabled us to select the mark-
ers with sufficient proof of prognostic power to be
validated in a prospective study.
The aim of the present work was to assess the
prognostic relevance of some biologic variables con-
sidered individually and their relative contribution
with respect to pathologic factors in node negative
breast cancer patients. Biologic variables repeatedly
or recently investigated were determined in parallel
on individual tumors in order to define their relative
prognostic contribution and their ability to identify
node-negative patients at risk.
Patients and methods
The clinic-biological study was conducted on a series
of 286 women with node-negative breast cancer re-
cruited by six clinical centers from 1989 to 1993.
At least 10, and a median of 16, axillary lymph
nodes were histologically examined. All patients had
loco-regional treatment; more than 50% underwent
quadrantectomy plus radiotherapy, and the remaining
patients underwent mastectomy. Adjuvant systemic
treatment was not given prior to relapse. The case
series was consecutive on the basis of the availabil-
ity of cell proliferation information. Patient distribu-
tion according to different age classes is reported in
Table 1. Median age was 55 years and about 60%
were postmenopausal patients, that is, more than 2
years had elapsed from spontaneous menopause or
ovariectomy at the time of diagnosis.
More than two thirds of tumors were 2 cm or less
in diameter and 18% were equal to or smaller than
1 cm. About 70% were ER-positive on the basis of
the 10 fmol cut off, and about 55% were PgR-positive
tumors on the basis of the 25 fmol cut off value.
Table 1. Clinico-pathologic and biologic characteristics
of the case series
Number Percentage
of cases
Age (years)
45 74 25.9
46–50 44 15.4
51–60 85 29.7
>60 83 29.0
Menopausal status
Premenopausal 113 39.5
Postmenopausal 173 60.5
Type of surgery
Quadrantectomy C RT 161 56.9
Mastectomy 122 43.1
Missing 3
Histotype
Lobular 26 9.2
Ductal 225 80.1
Others 30 10.7
Missing 5
Tumor size
1.0 cm 49 18.2
1.1–2.0 cm 139 51.7
>2.0 cm 81 30.1
Missing 17
Receptor status
ER  10 fmol 198 72.0
<10 fmol 77 28.0
Missing 11
PgR  25 fmol 132 54.5
<25 fmol 110 45.5
Missing 44
TLI
< 3.1% 143 50.0
 3.1% 143 50.0
c-erbB-2
Negative 131 57.2
Positive (any % of 98 42.8
positive cells)
Missing 57
p27
Negative 71 28.0
Positive (any % of 183 72.0
positive cells)
Missing 32
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Median TLI value was 3.1% which is in agreement
with the value reported in larger series [19–23]. Only
membrane staining was considered in scoring c-erbB-
2 positive cells; cytoplasmic staining was ignored as
aspecific immunoreaction. Clear p27 nuclear staining
was defined as positive. Positivity (any percentage of
positive cells) for c-erbB-2 and p27 was observed in
about 40% and 70% of tumors, respectively. Estrogen
v (ER) and progesterone (PgR) receptors were determ-
ined in the different centers, 3H-thymidine labeling
index (TLI) in only two centers (Forlì and Florence),
and c-erbB-2 and p27 expression was evaluated in the
Forlì laboratory.
Postoperative follow-up was carried out in the out-
patient clinic of all centers. All patients had a clinical
and instrumental check-up at 3-month intervals for the
first 2 years, every 6-months during the 3rd, 4th and
5th years, and subsequently once a year up to the 10th
year. Median follow-up was 74 months (range 4–111
months). Seventeen patients were lost to follow-up
(6%), of whom 11 after at least 40 months.
In vitro determinations
Immediately after surgery, part of the tumor material
was incubated with 3H-thymidine and then processed
for conventional histologic procedures for the determ-
ination of TLI, c-erbB-2 and p27 expression. The rest
of the tumor material was frozen in liquid nitrogen and
stored at −80C for ER and PgR determination.
TLI
Fresh tumor samples were incubated in culture me-
dium containing 3H-thymidine for 1 h at 37C and
fixed in formalin. The recent availability of a com-
mercial kit (Euroframe, Asti, Italy) enabled all the
participating centers to perform this first step of in
vitro 3H-thymidine labeling in their own laboratory.
Samples from all patients were then sent to the two ref-
eree centers (Forlì and Florence) for autoradiographic
procedures and TLI determination. Histologic sections
were dipped in a photographic emulsion (Ilford K5,
Ilford Photographics, London, UK) and exposed in
the dark for 3 days at 4C. Autoradiograms were de-
veloped in Ilford Phenprint for 6 min at 19C and
fixed in Hypam compound for 10 min. Samples were
stained with hematoxylin and eosin at 4C. When the
specimen was small enough to allow the radioactive
precursor to penetrate completely, labeled cells were
counted throughout the whole section; if not, count-
ing was limited to the periphery of the section (up to
80 µm in depth). TLI, expressed as the ratio between
thymidine-labeled cells and the total number of tumor
cells, was determined independently by two observers,
with 2,000–5,000 cells scored from different frag-
ments of the same tumor. Quality control procedures
were periodically repeated in the context of a National
Quality Control Program promoted by the Italian So-
ciety of Basic and Applied Cell Kinetics (SICCAB)
[24].
Steroid receptor content
ER and PgR were assayed by the dextran-coated char-
coal method according to the European Organization
for Research and Treatment on Cancer [25]. Quality
control procedures for hormone receptor dosage were
coordinated by the Italian ad hoc committee. Quant-
itative biochemical analysis was adopted to allow the
use of different cut off values and to identify different
steroid receptor content subgroups for future basic and
clinical analyses.
p27 and c-erbB-2 expression
Tumor samples were fixed in 10% formalin. 3 µm sec-
tions from paraffin-embedded blocks were deparaffin-
ized with xylene, rehydrated, and endogenous perox-
idase activity blocked. p27 antigen retrieval was per-
formed by means of microwaving at 750 W in 10 mM
citrate buffer (pH 6.0) for 15 min followed by cool-
ing at room temperature for 20 min. The sections were
then treated for non-specific binding with 3% bovine
serum albumin in PBS for 20 min. After this they
were incubated for 1 h at room temperature with p27
monoclonal antibody clone 57 (Transduction Labor-
atories, Lexington, KY) diluted 1:300 in PBS, for
15 min in biotynilated anti-mouse secondary antibody,
then rinsed and incubated with avidin–biotin conjug-
ate (Dako, LSABCkit). After washing in PBS, the
peroxidase reaction was developed to a brown stain by
0.05% diaminobenzidine, which was enhanced with
0.07% imidazole and hydrogen peroxide. Cell nuclei
were counterstained blue by Mayer’s haemalum and
the sections were mounted in Faramount (Dako).
For the determination of c-erbB-2 expression, the
sections were incubated for 1 h at room temperature
with the monoclonal antibody CB11, which recog-
nizes the internal domain of the c-erbB-2 protein
(HER-2/neu) (Biogenex, San Ramon, CA), diluted
1:50 in antibody diluent with Background Reducing
Components (DAKO Corporation, Carpinteria, CA).
At this concentration c-erbB-2 overexpressing tumor
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Table 2. Relationship between biologic variables and clinico-pathologic factors
TLI c-erbB-2 p27
Median value Median value of Median value of
% (range) positive cells % positive cells %
p (range) p (range) p
Age
 50 years 4.0 (0.01–16.8) 0.03 40 (5–90) 0.83 18.6 (1–93) 0.95
> 50 years 2.7 (0.01–17.0) 50 (5–100) 18.2 (1–100)
Menopausal status
Premenopausal 3.5 (0.01–15.0) 0.15 60 (5–90) 0.50 18.0 (1–93) 0.93
Postmenopausal 2.8 (0.01–17.0) 40 (5–100) 18.6 (1–100)
Histotype
Lobular 3.9 (0.2–15.0) 0.04 20 (5–50) 0.09 17.5 (1–97) 0.94
Ductal 2.8 (0.01–17.0) 50 (5–100) 18.6 (1–100)
Others 4.4 (0.01–16.8) 62 (5–90) 12.6 (1–98)
Tumor size
 1.0 cm 2.8 (0.2–11.0) 0.02 40 (5–90) 0.21 31.7 (1–100) 0.09
1.1–2.0 cm 3.2 (0.01–16.8) 35 (5–100) 13.9 (1–95)
> 2.0 cm 4.2 (0.2–17.0) 70 (5–100) 19.4 (1–97)
ER
 10 fmol 2.8 (0.01–15.0) 0.01 35 (5–100) 0.16 19.6 (1–100) 0.05
<10 fmol 4.3 (0.1–17.0) 65 (5–100) 8.4 (1–94)
PgR
 25 fmol 2.8 (0.01–15.0) 0.04 35 (5–90) 0.38 21.3 (1–98) 0.08
<25 fmol 4.0 (0.01–17.0) 55 (5–100) 13.1 (1–100)
cells showed a strong and focalized membrane stain-
ing.
At least 20 high-power fields were scored by two
independent observers for c-erbB-2 (FDP and AMG)
and p27 (FDP and PB). Immunoreactivity was ex-
pressed as the ratio between the percentage of stained
cells and the total number of tumor cells, or the entire
area of invasive neoplastic tissue for p27 and c-erbB-2,
respectively.
Statistical methods
The relationship between TLI, c-erbB-2, p27 and
clinico-pathologic or biologic factors was analysed us-
ing a non-parametric ranking statistic (Median test),
and Spearman’s correlation coefficient was used to
investigate the relationship between the different bio-
markers considered as continuous variables in indi-
vidual tumors.
Relapse-free survival was calculated as the period
from surgery until the date of the first documented
evidence of new disease manifestation in loco-regional
or distant sites, or in the contralateral breast. Owing
to the difficulty of distinguishing between a second
breast carcinoma and contralateral recurrence, the lat-
ter lesion was considered as an event. In the case of
a second primary cancer in a non-breast site, relapse-
free follow-up data were censored at the time of the
diagnosis of the second malignancy. All new disease
manifestations were assessed by clinical, radiologic
and, when feasible, histologic examination of the site
of relapse. Univariate analysis was performed tra-
cing Kaplan-Meier survival curves, and comparison of
survival curves was based on the log-rank test [26].
The role of each of the putative prognostic vari-
ables (univariate analysis) and their joint effect (mul-
tivariate analysis) was evaluated using Cox propor-
tional hazard models [27]. The analysis of the plot of
ln-ln(S(t)), (where S(t) is the Kaplan-Meier estimate of
the relapse-free survival curves), against the logarithm
of the time for each level of the factor studied, sugges-
ted that the assumption of proportional hazards was
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Table 3. Correlation between biologic variables
PgR TLI c-erbB-2 p27
rs p rs p rs p rs p
ER 0.444 <0.001 −0.197 0.001 −0.180 0.008 0.128 0.046
PgR −0.104 0.108 −0.269 <0.001 0.127 0.063
TLI 0.195 0.003 0.046 0.463
c-erbB-2 −0.042 0.535
Figure 1. Cut off values for predicting 5-year relapse-free survival plotted against the relative p values (———) and Odds ratio of relapse
(- - - - - - - - -) (A: tumor size; B: ER; C: c-erbB-2; D: TLI; E: PgR; F: p27).
generally correct [28]. In this model, the exponential
of each of the regression coefficients () is the odds
ratio (OR), which is assumed to be constant in time. In
univariate and multivariate analyses, the best putative
prognosis categories were used as references. The null
hypothesis i D 0 was tested by the Wald statistic. As
the prognostic variables were categorised, one or more
dummies were built for each of them.
The final model for multivariate analysis was ob-
tained using a backward stepwise procedure. Variables
that did not contribute significantly to the multivari-
ate Cox model (p> 0.05) were eliminated. A forward
stepwise procedure was also performed, obtaining the
same results as those of the backward procedure.
To evaluate the prognostic role of the different
parameters analysed in the study we tested differ-
ent cut off values ranging from the minimum to the
maximum value observed in our case series. Each di-
chotomy was used as an independent variable in a Cox
regression model to predict recurrence. Each model
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Table 4. Five-year relapse-free survival as a function of clinico-pathologic-
biologic variables
Number RFS (%) 95% CI Logrank p
of cases
Menopausal status
Premenopausal 113 76 68–84
Postmenopausal 173 79 72–85 0.01 0.935
Tumor size
 1.0 cm 49 94 87–100
1.1–2.0 cm 139 75 67–82
> 2.0 cm 81 73 63–83 7.75 0.021
TLI
<3.1% 143 83 76–89
 3.1% 143 72 65–80 5.83 0.016
ER
 10 fmol 198 76 70–82
<10 fmol 77 79 70–88 1.21 0.271
PgR
 25 fmol 132 71 63–79
<25 fmol 110 81 73–88 1.33 0.250
c-erbB-2
<40% 175 80 74–86
 40% 54 70 57–82 1.73 0.188
p27
 60% 218 80 75–86
> 60% 36 62 45–80 2.13 0.140
was evaluated with the Wald statistic and the one
with the smallest p value was identified. All p values
were based on two-sided testing and statistical ana-
lyses were carried out with SAS Statistical software
[29].
Results
The analysis of the relationship between biologic and
pathologic variables (Table 2) showed a significantly
higher proliferative activity in younger patients and
a suggestive, but not statistically significant, higher
TLI in pre- rather than in postmenopausal women.
Moreover, TLI median value increased as a function
of tumor size and was significantly higher in ER or
PgR negative tumors than in steroid receptor positive
tumors.
c-erbB-2 immunoreactivity was observed in about
40% of tumors and the percentage of immunoreacting
cells ranged from 5% to 100%. Neither the percent-
age of c-erbB-2 positive tumors nor the percentage
of positive cells were related to patient age or meno-
pausal status, whereas a higher, albeit not significantly
different, percentage of positive cells, was observed
in larger or steroid receptor negative tumors than in
smaller or steroid receptor positive tumors. Moreover,
a lower percentage of positive cells was observed in
lobular histotype than in ductal invasive histology.
p27 positivity was observed in more than 70% of tu-
mors and the percentage of positive cells ranged from
1% to 100%. A higher, but not significantly different
(pD 0.09) frequency of immunoreacting cells was ob-
served in tumors  1 cm. The percentage of positive
cells was also higher in estrogen receptor (pD 0.05) or
progesterone receptor positive (pD 0.08) tumors than
in steroid receptor negative tumors.
The analysis of different markers analysed as con-
tinuous variables (Table 3) showed a significantly dir-
ect relation between c-erbB-2 and TLI, and an inverse
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Figure 2. Relapse-free survival curves as a function of different prognostic variables.
relation between c-erbB-2 and ER and PgR. Moreover,
p27 expression was significantly directly related to
steroid receptor status but not to c-erbB-2 expres-
sion or proliferative activity. However, even when
significant associations were observed, the correlation
coefficients were very poor.
For the prognosis evaluation, tumor size, TLI, c-
erbB-2 and p27 expression, and ER and PgR content
were analysed as continuous or dichotomous vari-
ables. When considered as a continuous variable,
pathologic tumor size showed the unique discriminant
cut off value of 1 cm as predictor of risk of relapse at
5 years. TLI was able to identify subgroups of patients
with a significantly different probability of relapse-
free survival starting from the 3.0% of thymidine
labeled cells. The odds ratio progressively increased
as TLI value increased. Conversely, no value of
c-erbB-2 or p27 expression and ER or PgR content
reached statistical significance as predictors of relapse
(Figure 1).
In the present case series of node negative pa-
tients, 5-year relapse-free survival was 77% (95%
CI 73–82%), in agreement with the results repor-
ted in most clinical studies. When biologic markers
were analysed as dichotomous variables using conven-
tional cut off values or the most discriminant values
detected by the previous analyses on continuous vari-
ables, a significantly lower relapse-free survival at 5
years was observed for patients with tumors larger
than 1 cm or rapidly proliferating tumors than in pa-
tients with smaller (pD 0.021) or slowly proliferating
tumors (pD 0.016). Conversely, 5-year relapse-free
survival was not related to c-erbB-2 or p27 expression
when median values, other values or negativity versus
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Table 5. Results from backward application of Cox model (260 patients, 68 events)
Step Factor Odds ratio 95% CI p
Relapse free survival
1 Tumor size 3.34 1.21–9.18 0.019
(> 1 cm vs  1 cm)
2 TLI ( 3.1% 1.78 1.07–2.95 0.027
vs <3.1%)
Factors not entered
ER status ( 10 fmol 1.44 0.82–2.53 0.204
vs <10 fmol)
Menopausal status 1.05 0.64–1.71 0.847
(post vs pre)
positivity were considered as criteria. Similarly, the
conventional ER and PgR cut off values, as well as
any other value, did not identify subgroups of patients
at different probabilities of 5-year relapse-free survival
(Table 4).
The profile of relapse-free survival curves over
time (Figure 2) showed significantly distinct curves
for patients with small and large tumors. Similarly,
significantly different relapse curves were observed
for patients with slowly or rapidly proliferating tu-
mors. In particular, diversification started from the first
year and progressively increased up to the 5th year of
follow-up.
Conversely, relapse-free survival analysed as a
function of c-erbB-2 expression showed a higher risk
in patients with tumors with a high rather than low c-
erbB-2 expression. The difference increased starting
from the 1st year up to the 3rd year and then tended
to diminish progressively. The curves appeared to be
getting closer together at the 5th year follow-up. Over-
all, the relapse-free survival risk was not significantly
different for the two biologic subgroups. The relapse-
free survival curves for patients with weakly or highly
p27-expressing tumors were not significantly different
and were superimposible, at least up to the 3rd year.
The variables which individually proved to be pro-
gnostic indicators, that is tumor size and TLI, in
addition to ER status and menopausal status which
have long been considered to be important indicators
of the natural history of breast cancer, were tested
in multivariate analysis. Only tumor size and, among
the biologic variables investigated, cell proliferation,
maintained their independent prognostic relevance on
relapse-free survival (Table 5). Relapse-free survival
curves for the four subgroups defined by the independ-
Figure 3. Relapse-free survival from the multivariate analysis.
ent prognostic variables identified by multivariate ana-
lysis are shown in Figure 3. For patients with tumors
 1 cm, 5-year relapse-free survival was 94.5% (95%
CI 89.1–100.0) when TLI was lower, and 89.9% (95%
CI 80.7–100.0) when TLI was higher than  3.1%. In
patients with tumors > 1 cm, 5-year relapse-free sur-
vival was 81.8% (95% CI 74.5–89.0) when TLI was
low and 68.6% (95% CI 61.0–77.1) when TLI was
high.
Discussion
Our study, performed on a large series of node-
negative breast cancer patients given loco-regional
treatment alone, showed, for the first time in a pro-
spectively recruited series, the prognostic relevance
of TLI and its independence from other clinico-
pathologic and biologic factors over a 5-year follow-
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up period. These results confirm that tumor prolifer-
ative activity, evaluated as TLI, is a strong and repro-
ducible indicator of tumor aggressiveness, as already
proven by pilot and confirmatory retrospective studies
on very large series of cases and with longer follow-up
periods [30–41].
The reproducibility of TLI as an indicator of
relapse-free survival and survival is favoured by the
unequivocal autoradiographic image of labeled cells
as compared to the modulation of immunohistochem-
ical images, and guaranteed by an ongoing National
Quality Control Program, which was activated in
Italy almost 10 years ago [24]. Therefore, TLI rep-
resents an important variable for identifying patients
with negative lymph-node tumors at risk who are thus
candidates for adjuvant systemic therapy. Pathologic
tumor size was also an independent prognostic indic-
ator with a 94% disease-free probability at 5 years
for patients with very small tumors. In contrast, in
the present series of patients, hormonal receptor status
did not affect the 5-year incidence of new disease
manifestation. Moreover, the four subgroups defined
according to TLI and pathologic tumor size, which
were the only two independent prognostic variables
identified by multivariate analysis, showed a signific-
antly different risk of relapse. The risk was lowest
for the subgroups of patients with the two favourable
prognostic variables (about 5%) and more than six
times higher for patients with the two unfavourable
prognostic variables.
The fraction of c-erbB-2 expressing cells was not
related to either patient age or menopausal status.
In contrast, it was noticeably higher in ductal than
in lobular histotype, in agreement with other results
[42], and, as already reported, progressively increased
as tumor size increased [43–46] and steroid receptor
content decreased [42, 43, 47–51]. Moreover, we con-
firmed the relation between c-erbB-2 and cell prolifer-
ation. As far as we know, the only two papers which
to date have investigated the relationship between c-
erbB-2 expression and TLI in breast cancer found a
significant association between high TLI and positive
staining in both in situ [52] and invasive carcinoma
[53].
The results on the prognostic value of c-erbB-2
are still somewhat contradictory, with the majority
of studies reporting no prognostic relevance in node-
negative breast cancers [42, 54–57]. The controversial
results have been tentatively ascribed to the different
follow-up periods considered in the studies [42]. The
results from the present work appear to reinforce this
hypothesis, identifying, for the first time experiment-
ally, c-erbB-2 expression as a short-term prognostic
indicator. This finding further confirms the lack of
long-term prognostic relevance of c-erbB-2, which,
conversely, remains a potential predictor of response
to hormonal therapy and to different antitumor drugs
[58–63].
Similarly, the cell cycle inhibitor p27 was more
frequently expressed in lobular than in ductal his-
totypes, but the difference did not reach statistical
significance, probably due to unbalanced subgroups,
and was inversely related to tumor size and directly
related to steroid receptor content. In our case series
of node-negative breast cancer patients treated with
loco-regional therapy alone, p27 expression was not
related to disease-free survival. This result cannot eas-
ily be compared with the findings obtained in other
studies on large series of breast cancer patients. No
information on the frequency of positive or negative
p27 tumors is reported and the generally used semi-
quantitative analysis is not a guarantee of equivalent
evaluation criteria, even though similar cut off val-
ues of p27 positive cells were adopted in most of the
studies for follow-up analysis. A prognostic relevance
of p27 expression was observed in studies including
both node-positive and node-negative patients con-
sidered as one group and treated with different types of
chemotherapy or hormone therapy [64], or for whom
treatment modalities are not specified [65–67]. The
results on node negative patients are less consistent.
In fact, a relation between the cell cycle inhibitor and
clinical outcome was reported by Porter [67] and Wu
[66] but not by Tan [64], who performed, as we did,
a quantitative analysis of the percentage of p27 posit-
ive cells. However, it must also be pointed out that in
all these studies, node-negative patients were treated
with different types of systemic therapy, whereas our
analysis was performed for the first time, as far as we
know, on node-negative patients who underwent only
loco-regional therapy. Our results are in agreement
with those from a similar study recently published by
Reed et al. [68].
In conclusion, TLI remains, in our experience, a
variable of important clinical relevance by intrinsically
containing both prognostic and predictive information
on response to chemo- and hormone therapy [69–
73]. Therefore, once node negative patients at risk
have been identified on the basis of tumor size and
cell proliferation, TLI, together with steroid recept-
ors and c-erbB-2 expression, could open a new era of
individually-tailored therapy for patients.
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